Pharma AI leaders should start with data inventory, lineage, consent history, and access governance before deployment. Agentic AI can only be trusted when teams know what the data is, where it came from, how it was collected, and whether its use was authorized. Without that context, organisations risk regulatory exposure, flawed outputs, and patient harm across jurisdictions.
Why This Matters for Security Teams
In pharma, internal data governance is not just a compliance exercise. agentic ai systems can combine research notes, trial records, quality documents, and operational data in ways that amplify whatever weaknesses already exist in classification, consent handling, and access controls. Current guidance from NIST AI Risk Management Framework and agentic AI threat research makes one point clear: if data provenance is unclear, the system inherits that uncertainty at runtime.
Teams often focus on model selection and prompt design while underestimating the governance of the data feeding the agent. That is where risk compounds. A dataset may be technically available, but still inappropriate for agentic use because consent language is too narrow, retention limits have expired, or regional restrictions prohibit reuse for certain automated decision flows. In regulated environments, those gaps can lead to bad recommendations, contaminated outputs, and avoidable audit findings.
The practical issue is that agentic systems do not merely read data. They can retrieve, synthesize, and act on it across tools and workflows, so governance must cover both origin and intended use. Security, privacy, legal, and scientific stewardship all need a shared view of the data estate. In practice, many pharma teams discover these failures only after an agent has already exposed restricted data or produced an unsafe recommendation, rather than through intentional governance review.
How It Works in Practice
Governance starts with a data inventory that is detailed enough to support decision-making. For each dataset, teams should record ownership, lineage, collection purpose, consent or contractual basis, jurisdictional restrictions, sensitivity class, retention period, and approved downstream uses. For agentic AI, that record should also indicate whether the dataset may be used for retrieval, fine-tuning, evaluation, tool actions, or human review support.
Pharma leaders should treat provenance and authorization as control points, not paperwork. If a dataset originated in a clinical study, for example, its reuse may be constrained by protocol, ethics approval, or patient consent language. If the data includes manufacturing or quality records, the concern may shift to integrity, traceability, and segregation of duties. The governance question is always the same: is this data allowed to inform this automated action in this context?
A workable control model usually includes:
- data classification tied to permitted AI use cases
- lineage tracking from source system to agent context window
- access review for humans, service accounts, and other non-human identities
- validation checks for completeness, recency, and known bias
- blocking rules for restricted records, including patient, partner, or export-controlled data
Security leaders should align this work with NIST Cybersecurity Framework 2.0 for governance and protection functions, and pair it with control evidence from NIST SP 800-53 Rev 5 Security and Privacy Controls. Where agentic workflows rely on retrieval or autonomous tool use, OWASP Agentic AI Top 10 and the CSA MAESTRO agentic AI threat modeling framework help teams identify where poisoned, stale, or overexposed data can become an execution risk. These controls tend to break down when data lives across legacy research repositories and SaaS platforms because lineage and permission evidence become fragmented across owners and regions.
Common Variations and Edge Cases
Tighter data governance often increases operational overhead, requiring organisations to balance speed of AI enablement against legal and scientific assurance. That tradeoff is especially visible in pharma, where cross-border collaboration, trial partnerships, and vendor-managed platforms can complicate consent and residency decisions.
There is no universal standard for how much historical data can be safely reused in agentic AI, so current guidance suggests adopting tiered approvals rather than a single enterprise-wide rule. High-risk uses, such as agents that support clinical, safety, or quality decisions, should face stricter review than internal summarisation or knowledge discovery use cases. Best practice is evolving, but one principle is stable: if a dataset cannot be explained to an auditor, it should not be trusted by an autonomous system.
Edge cases often appear when metadata is incomplete, when datasets are de-identified but still re-identifiable in combination, or when local law differs from global policy. For those situations, pharma leaders should require explicit exception handling, documented risk acceptance, and periodic revalidation. Threat modelling should also consider AI-specific abuse paths, including prompt injection against retrieval sources and indirect exposure through tool outputs, as highlighted by MITRE ATLAS adversarial AI threat matrix and recent AI incident reporting such as Anthropic — first AI-orchestrated cyber espionage campaign report. The strongest programmes treat data governance as a living control, not a one-time inventory.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
OWASP Agentic AI Top 10 and MITRE ATLAS address the attack and risk surface, while NIST AI RMF, NIST CSF 2.0 and NIST SP 800-63 set the governance and control requirements practitioners need to meet.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST AI RMF | AI risk governance requires documented data provenance and intended-use controls. | |
| OWASP Agentic AI Top 10 | Agentic apps are exposed to retrieval abuse, prompt injection, and unsafe tool use. | |
| NIST CSF 2.0 | GV.DR, PR.DS | Data governance and protection map directly to control ownership and data handling. |
| NIST SP 800-63 | Identity proofing matters when humans approve data access or exception workflows. | |
| MITRE ATLAS | AML.TA0001 | Adversarial AI techniques include poisoning and data manipulation upstream of the model. |
Use GOVERN and MAP functions to define approved data use, ownership, and escalation paths.
Related resources from NHI Mgmt Group
- How should security teams govern on-prem data that is also accessed by automation and AI systems?
- How should security teams govern data access for agentic AI workflows?
- How should security teams govern sensitive data used by AI systems?
- How should organisations govern access to data used by AI systems?
Deepen Your Knowledge
Reviewed and updated by the NHIMG editorial team on August 24, 2026.
NHI Mgmt Group — the #1 independent authority on Non-Human Identity, IAM, and Agentic AI security. nhimg.org
